Polymeric anticancer drugs with pH-controlled activation

被引：443

作者：

Ulbrich, K ^{[1
]}

Subr, V ^{[1
]}

机构：

[1] Acad Sci Czech Republ, Inst Macromol Chem, CR-16206 Prague 6, Czech Republic

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2004年 / 56卷 / 07期

关键词：

drug delivery; drug release; drug targeting; drug carriers; polymer prodrugs; pH-sensitivity; acid-sensitive; cancer;

D O I：

10.1016/j.addr.2003.10.040

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Use of macromolecular water-soluble carriers of anti-cancer drugs represents a promising approach to cancer therapy. Release of drugs from the carrier system is a prerequisite for therapeutic activity of most macromolecular anti-cancer conjugates. Incorporation of acid-sensitive spacers between the drug and carrier enables release of an active drug from the carrier in a tumor tissue. either in slightly acidic extracellular fluids or, after endocytosis, in endosomes or lysosomes of cancer cells. This paper reviews advances in development and study of properties of various acid-sensitive macro molecular drug delivery systems, starting from simple polymer-drug conjugates to ending with site-specific antibody-targeted polymer-drug conjugates. (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：1023 / 1050

页数：28

共 148 条

[1] INHIBITION OF HUMAN-TUMOR GROWTH IN NUDE-MICE BY A CONJUGATE OF DOXORUBICIN WITH MONOCLONAL-ANTIBODIES TO EPIDERMAL GROWTH-FACTOR RECEPTOR [J].

ABOUDPIRAK, E ;

HURWITZ, E ;

BELLOT, F ;

SCHLESSINGER, J ;

SELA, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3778-3781

[2]

Akamatsu K, 1999, J PHARMACOL EXP THER, V290, P1242

[3] Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric prodrug of prostaglandin E1 using lactosylated poly(L-glutamic hydrazide) as a carrier [J].

Akamatsu, K ;

Yamasaki, Y ;

Nishikawa, M ;

Takakura, Y ;

Hashida, M .

BIOCHEMICAL PHARMACOLOGY, 2001, 62 (11) :1531-1536

[4]

Alberts B., 2002, Molecular Biology of The Cell, V4th

[5] Ligand-targeted therapeutics in anticancer therapy [J].

Allen, TM .

NATURE REVIEWS CANCER, 2002, 2 (10) :750-763

[6] SYNTHESIS, CONTROLLED-RELEASE PROPERTIES AND ANTITUMOR-ACTIVITY OF ALGINATE-CIS-ACONITYL-DAUNOMYCIN CONJUGATES [J].

ALSHAMKHANI, A ;

DUNCAN, R .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 122 (1-2) :107-119

[7] Targeting the prostate for destruction through a vascular address [J].

Arap, W ;

Haedicke, W ;

Bernasconi, M ;

Kain, R ;

Rajotte, D ;

Krajewski, S ;

Ellerby, HM ;

Bredesen, DE ;

Pasqualini, R ;

Ruoslahti, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (03) :1527-1531

[8] Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil [J].

Beyer, U ;

Roth, T ;

Schumacher, P ;

Maier, G ;

Unold, A ;

Frahm, AW ;

Fiebig, HH ;

Unger, C ;

Kratz, F .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (15) :2701-2708

[9] Differences in the intracellular distribution of acid-sensitive doxorubicin-protein conjugates in comparison to free and liposomal formulated doxorubicin as shown by confocal microscopy [J].

Beyer, U ;

Rothen-Rutishauser, B ;

Unger, C ;

Wunderli-Allenspach, H ;

Kratz, F .

PHARMACEUTICAL RESEARCH, 2001, 18 (01) :29-38

[10]

BRASLAWSKY GR, 1990, CANCER RES, V50, P6608

← 1 2 3 4 5 6 7 8 9 10 →